Genmab-CEO: Janssen is the ideal partner
Janssen Biotech is the ideal company to help develop Ofatumumab, and also the company that provided the best conditions, says Genmab’s CEO. In the future, however, the company wants to market its own drugs.
af KRESTEN MORTEN MUNKSGAARD
“This is a deal that will change Genmab as a company and stabilize it financially. It gives us the opportunity to use the full potential of daratumumab.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
